NEW YORK, May 22, 2017 /PRNewswire/ -- Harwood Feffer LLP
(www.hfesq.com) is investigating potential claims against officers
and directors of Trinity Biotech plc ("Trinity" or the "Company")
(NASDAQ: TRIB).
On October 4, 2016, Trinity
disclosed that that U.S. Food and Drug Administration ("FDA") had
recommended that the Company withdraw its premarket notification
submission for the Meritas Troponin-I Test and Meritas
Point-of-Care-Analyzer. Trinity further announced that based
on the FDA's recommendation the Company would withdraw the
submission, close one of its facilities and take a noncash
write-off of over $50 million.
On this news, Trinity's American Depositary Shares ("ADSs") lost
nearly 50% of their value, and have not recovered.
Our investigation concerns whether the Company and its officers
and directors omitted to disclose material information and/or
issued misleading disclosures in connection with the foregoing.
If you own Trinity American Depositary Shares and wish to
discuss this matter with us, or have any questions concerning your
rights and interests with regard to this matter, please
contact:
Robert I. Harwood, Esq.
Benjamin I. Sachs-Michaels, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
(212)935-7400
Email: bsachsmichaels@hfesq.com
Website: http://www.hfesq.com
Follow us on Twitter: @HarwoodFeffer
Harwood Feffer has been
representing individual and institutional investors for many years,
serving as lead counsel in numerous cases in federal and state
courts. Please visit the Harwood Feffer LLP website
(http://www.hfesq.com) for more information about the
firm.
Attorney Advertising. The law firm responsible for this
advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results
do not guarantee or predict a similar outcome with respect to any
future matter.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/harwood-feffer-llp-announces-investigation-of-trinity-biotech-plc-300461792.html
SOURCE Harwood Feffer LLP